logo
Plus   Neg
Share
Email

Amgen : EVENITY Gets Positive CHMP Opinion For Treatment Of Severe Osteoporosis

Amgen (AMGN) and UCB said that the Committee for Medicinal Products for Human Use or CHMP of the European Medicines Agency or EMA has adopted a positive opinion recommending Marketing Authorization for EVENITY or romosozumab for the treatment of severe osteoporosis in postmenopausal women at high risk of fracture and with no history of myocardial infarction or stroke.

EVENITY is a novel bone-builder with a dual effect that increases bone formation and to a lesser extent reduces bone resorption or bone loss.

The European Commission, which has the authority to approve medicines for use throughout the European Union, will review the CHMP's recommendation. A European Commission decision is expected by year-end 2019.

EVENITY is approved in U.S. for the treatment of osteoporosis in postmenopausal women at high risk for fracture.

EVENITY is also approved in Japan and South Korea for the treatment of osteoporosis for women and men at high risk for fracture, in Canada for the treatment of osteoporosis for postmenopausal women at high risk for fracture, and in Australia for the treatment of osteoporosis in postmenopausal women at high risk of fracture and as a treatment to increase bone mass in men with osteoporosis at high risk of fracture.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
J. M. Smucker Co. is recalling certain Natural Balance canned cat food, citing health concerns likely associated with increased levels of choline chloride, an animal growth promotant, the U.S. Food and Drug Administration said in a statement. The recall was initiated after receiving reports of adverse reactions. Polaris Industries Inc. is recalling certain Ranger and General Utility, as well as All-Terrain vehicles citing risks of crash, the U.S. Consumer Product Safety Commission said in a statement. The Medina, Minnesota-based company has called back about 26,730 units of Model Year 2019 - 2020 Ranger XP 1000 & Model Year 2020 General XP 1000 Utility vehicles. Gilead Sciences Inc. (GILD) said Friday that the European Commission has granted conditional marketing authorization for Veklury or remdesivir as a treatment for SARS-CoV-2 infection, the virus that causes COVID-19.
Follow RTT